Abbott triggered by positive earnings
Abbott Laboratories Second-Quarter Results Beat Expectations Despite Lower COVID-19 Testing Sales
The company now anticipates about $1.3 billion in sales from COVID-19 testing products for 2023, compared with the prior forecast of $1.5 billion, "due to current testing dynamics, including lower demand for testing following the end of the public health emergency in May," Chief Financial Officer Robert Funck said on the call.
For the third quarter, Abbott anticipates adjusted earnings of roughly $1.10 per share, according to Funck. Analysts estimate EPS of $1.11.
Technicals:
Cycle Sniper Reversal Filter Headed Nort
Cycle Sniper Bullish ddeviation
Key Resistance: 116 $
Closing above 116 $
Targets: 122 $ and 128 $
The company now anticipates about $1.3 billion in sales from COVID-19 testing products for 2023, compared with the prior forecast of $1.5 billion, "due to current testing dynamics, including lower demand for testing following the end of the public health emergency in May," Chief Financial Officer Robert Funck said on the call.
For the third quarter, Abbott anticipates adjusted earnings of roughly $1.10 per share, according to Funck. Analysts estimate EPS of $1.11.
Technicals:
Cycle Sniper Reversal Filter Headed Nort
Cycle Sniper Bullish ddeviation
Key Resistance: 116 $
Closing above 116 $
Targets: 122 $ and 128 $
For alerts,special reports,news and singals over 15.000 + instruments our free discord channel
discord.gg/4DrmXHfvnG
About AI Discord Channel: bit.ly/470HjmP
Ücretsiz Discord Kanalımız
discord.gg/4DrmXHfvnG
discord.gg/4DrmXHfvnG
About AI Discord Channel: bit.ly/470HjmP
Ücretsiz Discord Kanalımız
discord.gg/4DrmXHfvnG
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.